|Bid||80.50 x 800|
|Ask||81.73 x 1100|
|Day's Range||80.16 - 81.70|
|52 Week Range||75.77 - 122.00|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||22.09|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||4.28 (5.32%)|
|1y Target Est||92.71|
Announcement: Moody's announces completion of a periodic review of ratings of AbbVie Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
The tax overhaul has given pharmaceutical companies that generate hefty sales outside the U.S. the chance to bring cash home at a preferential rate. Multinational drug companies were big beneficiaries from the tax overhaul because they generate a good chunk of their sales outside the U.S. and had been keeping billions of dollars overseas to avoid having to pay U.S. taxes on the sums. With taxes falling, drug-company profits have soared, according to a Wall Street Journal review of securities filings for the first nine months of 2018.
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In this era of increased stock market volatility, a dividend focused approach can give peace of mind and likely a better chance at above average returns, suggests income expert Tim Plaehn, editor of The Dividend Hunter.
High-growth stocks draw the lion's share of the attention in financial media. These securities usually show higher levels of volatility and often represent the future of the American economy. Today, these equities often revolve around new technologies like AI, VR and the Internet of Things (IoT).However, concepts that we might consider "new again" also draw this interest. Due to decades of suppression, cannabis has become one of these areas. Also, judging by the performance of Chipotle (NYSE:CMG), even equities revolving around fast food can turn into high-growth stocks with the right approach. * 10 Best Dividend Stocks to Buy for the Next 10 Months As one might expect, the overwhelming majority of these stocks carry the high P/E ratio that goes along with elevated growth. However, not all prospective buyers want that level of risk. Fortunately, a few high-growth stocks also fall into the "undervalued stocks" category. The following equities constitute some of the best stocks for combining growth with value:InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock AbbVie (ABBV)Drug equities don't often make lists of high-growth stocks. AbbVie (NYSE:ABBV) formed in 2013 when it split from Abbott Laboratories (NYSE:ABT). It constitutes what was once Abbott's pharma division.ABBV stock has suffered in recent months as its old blockbuster drug, Humira, faces patent expirations in many countries. However, AbbVie's drug pipeline has received favorable reviews. For this reason, most analysts believe that a new drug or a combination of future best sellers will more than replace the income lost from generic versions of Humira.Still, due to the uncertainty, ABBV stock trades at only 8.4 times forward earnings. However, even with a single-digit P/E ratio, Wall Street predicts 10.6% profit growth for 2019. They also believe the average increase will come in at almost 13.4% per year over the next five years.ABBV also offers one key benefit stemming from its former association with Abbott -- dividend aristocrat status. Walking away from its 46-year streak of payout hikes would put ABBV stock at risk. Hence, one can assume the increases will continue. Their board also approved a 40% increase in 2018 and a 19% hike for this year. Given the pressure to raise dividend payments every year, this is a remarkable show of confidence. Moreover, thanks to a lower stock price and higher dividends, the yield now stands at 5.4%.Investing in ABBV stock now involves some faith. However, with a single-digit P/E, double-digit profit growth, and a generous, growing dividend, investors could receive tremendous rewards for believing.Source: Apple Apple (AAPL)With its $800 billion market cap and massive slide last fall, Apple (NASDAQ:AAPL) might seem like a strange choice for a high-growth stocks list. Indeed, both the stock and the earnings projection saw a considerable move lower as iPhone sales fell well short of initial estimates. Also, laws of mathematics weigh on growth. An increase in AAPL's market cap of just 10% would mean $80 billion in growth, eight times the minimum size of a large-cap stock.However, as smartphone prices fall, Apple is working to make itself less iPhone-dependent. It no longer reports iPhone unit sales. Moreover, moves into services and healthcare should bring new sources of revenue.Due to tepid iPhone sales, profit growth for the year will come in at only 0.3%. But it should reclaim its high-growth status assuming the predicted 11.5% growth (and higher in the years after) comes to pass. * 7 Bank Stocks to Buy After the BB&T-Suntrust Mega-Merger AAPL stock may suffer for a time as it works to diversify sales away from the iPhone. However, with its enormous cash hoard and its ability to pioneer new technologies, AAPL stock will remain a solid growth story as it works to reclaim its $1 trillion market cap.Source: Shutterstock CannTrust (CNTTF)I normally would not place an equity with a 51.5 trailing P/E ratio in the "cheap" category, but compared to peers in the cannabis space, CannTrust (OTCMKTS:CNTTF) remains inexpensive. Although one can place almost every marijuana equity in the "high-growth stocks" category right now, CannTrust stands out with its consistent profitability.For those concerned about the OTC listing, CannTrust applied to trade on the NYSE last month. Once that listing occurs, more traders can buy it, so it should see some increase at that time.As most know, the Canadian marijuana boom came to an abrupt end in October when the product gained full legal status in Canada. However, legalization of one form of cannabis, hemp, has reignited this boom south of the Canadian border. The equities of larger peers such as Canopy Growth (NYSE:CGC) have already recovered most of the losses which occurred following legalization in Canada. CNTTF stock has also risen by more than 60% from its December low.Even if full legal status does not come soon, both hemp and CBD-related products alone should allow for massive growth across the U.S. With its specialty in cannabis oils, CannTrust should benefit. The company also expanded into Europe by becoming the first and only foreign seller of cannabis oil in Denmark beginning in October.At this moment, most cannabis equities could be described as high-growth stocks. However, with its relatively low P/E, its focus on cannabis oil, and the move to the NYSE, CannTrust delivers this growth at a lower risk compared with its key peers.Source: Qualcomm Qualcomm (QCOM)Qualcomm (NASDAQ:QCOM) stock has suffered in recent years. A long-running legal dispute with Apple has resulted in the exclusion of Qualcomm chips from the later models of the iPhone. This and other legal battles regarding its licensing practices have weighted on QCOM. As a result, the stock trades nearly 40% below a multi-year high last seen in 2014.However, a great deal of anticipation surrounds its 5G-capable Snapdragon 855 chip. Carriers have begun to launch 5G networks, and most expect 5G capable phones to see a wide release beginning later this year. While QCOM's chip will not appear in the iPhone, makers of Android-powered smartphones have shown an interest. As a result, analysts believe that profit increases will again see double-digit increases beginning in 2020. After years of profit declines, Wall Street predicts that annual growth will average 10.7% per year over the next five years. This will occur just as the company's forward P/E ratio falls to around 11.6.QCOM stock has also quietly developed a reputation as a dividend-paying stock. Despite declining profits in past years, Qualcomm has hiked its payout for eight years in a row. As a result of the increases and the lower stock price, the dividend yield has risen to about 4.9%. * 7 Breakout Stocks In Early 2019 Yes, its dispute with Apple has weighed on the stock. However, thanks to 5G, the company has developed a new source of revenue. Investors can also collect a generous dividend while waiting for 5G to revive QCOM. Thanks to that dividend, QCOM stock should pay off even if it does not pay off in growth.Source: Shutterstock Spirit (SAVE)Spirit (NYSE:SAVE) has offered value and growth to an industry not known for fostering high-growth stocks: airlines. For decades, Southwest (NYSE:LUV) brought innovation to the industry as its take on air travel brought lower fares, profits, and high-growth to a stagnant, unprofitable industry.Today, Spirit leads that charge. As the leader of the ultra-low-fare segment of the industry, it continues to see massive profit growth and expansion in both domestic and international markets. Spirit has won over price-sensitive customers who will trade perks such as in-flight beverages and carry-on bags for lower costs.Like Southwest, Spirit has depended on one plane type. However, the company now plans to add a type of regional jet to its fleet. This will allow SAVE to bring low fares to smaller markets dominated by legacy carriers.Even without smaller markets, it has already seen growth numbers that shoot toward the stratosphere. Analysts forecast profit growth of 45.7% for 2019. They also believe earnings increases will average above 20% per year for the foreseeable future.Despite this growth, Spirit, like other airlines, has struggled to achieve higher P/E ratios. This may explain why its multiple is only slightly higher than slower-growth airlines such as American (NASDAQ:AAL) or Delta (NYSE:DAL). SAVE's forward P/E currently stands at around 9.6.Admittedly, few gravitate to airlines when looking for cheap, high-growth stocks. However, the massive profit growth and continuous expansion show that Spirit has become the king of the ultra-low-fare airline sector. Driven by small markets and foreign expansion, profits should continue to climb.As of this writing, Will Healy is long ABBV and CNTTF stock. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Fundamentally Sound Dividend Stocks to Buy * 5 Reasons Reeling FAANG Stocks Won't Deliver Big Returns * 3 Reasons Canopy Growth Could Burn You Compare Brokers The post 5 High-Growth Stocks Undervalued by the Market appeared first on InvestorPlace.
NORTH CHICAGO, Ill. and MENLO PARK, Calif. , Feb. 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic ...
AbbVie or Celgene: Which Is the Better Biotech Bet This Month?(Continued from Prior Part)Comparing dividend projectionsAbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.Analysts expect AbbVie’s
AbbVie or Celgene: Which Is the Better Biotech Bet This Month?(Continued from Prior Part)Growth driversAbbVie (ABBV) expects its leading immunology asset, Humira, and its hematology-oncology franchise, which is made up of Imbruvica and Venclexta, to
AbbVie or Celgene: Which Is the Better Biotech Bet This Month?(Continued from Prior Part)Expense guidance in 2019 On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an R&D (research and development) expense-to-sales ratio of
AbbVie Inc NYSE:ABBVView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABBV totaled $16.98 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
AbbVie or Celgene: Which Is the Better Biotech Bet This Month?(Continued from Prior Part)Margin projections for 2019 On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019, up 270 basis
AbbVie or Celgene: Which Is the Better Biotech Bet This Month?(Continued from Prior Part)Revenue guidance for 2019On its fourth-quarter earnings conference call, AbbVie (ABBV) projected a 1% YoY (year-over-year) operational revenue growth rate and a
AbbVie or Celgene: Which Is the Better Biotech Bet This Month?Share price movements On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77, and 34.68% lower than its
Drugmakers Pfizer Inc, Bristol-Myers Squibb Co and Sanofi SA said on Wednesday that their chief executives plan to testify at a Senate hearing on rising prescription drug prices later this month. Johnson & Johnson said on Wednesday that Jennifer Taubert, its head of global pharmaceuticals, would represent the healthcare conglomerate at the hearing.
Pfizer, Merck and Sanofi have agreed to send their CEOs to Washington. AstraZeneca said it is reviewing the request. Bristol-Myers Squibb and Johnson & Johnson have not said whether they'll testify.
Although many biotech stocks have been hit hard at the start of 2019 while the general market has rallied, this underperformance in the biotechnology space has presented at least two key benefits for investors looking to invest in the area. First, and perhaps the most obvious, is that being able to enter biotech stocks at a cheaper price -- assuming the companies are not fundamentally broken -- is much better than going in while the stocks are overpriced or in "rally mode". Second, in situations like this, companies' dividend yields go up. What all of this means is that despite the seemingly grim picture for biotech, there are actually several solid biotech dividend stocks to invest in now. The struggle is sifting through all the names and finding which of them are the best dividend stocks to invest in. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 F-Rated Stocks That Could Break Your Portfolio But don't worry, I've done the hard work for you. Below are three of the best biotech dividend stocks to buy now. Source: Shutterstock ### AbbVie (ABBV) AbbVie (NYSE:ABBV) trades at a modest price-to-earnings ratio of 21X, while shares yield 5.45%. Although short-term investors might be concerned that ABBV shares have been on a downtrend since topping in May 2018 at $122, there is still plenty of longer-term potential in ABBV to be hyped about. Much of the downside ABBV experienced occurred after its latest earnings report. AbbVie reported fourth-quarter adjusted profits that grew a solid 28% over last year; at $1.90 a share, the company achieved its guidance for the quarter. But the stock gave up around $10 a share, falling from $88 to around $78, after the report. Investors fretted over the 15% drop in international Humira sales. Biosimilar competition in Europe, which makes up 75% of its international Humira business, was expected. However, generic competition for its flagship drug does not concern ABBV management. It's likely that they're banking on a slew of new product releases in 2019 to offset the aggressive discounting from competitors. In fact, AbbVie is funding five major products for launch indications this year. This should drive revenue higher and lead to double-digit earnings-per-share growth for the company. All of which makes it one of the notable biotech dividend stocks to buy. Source: Everjean via Flickr ### Allergan (AGN) Allergan plc (NYSE:AGN) ended its last rally in October 2018, with AGN shares finally bottoming by the end of last year at around $130. The stock fell again from $160 to a recent price of $144 after reporting Q4 results. Right now, AGN shares will pay you a modest 2.1% dividend. And if the stock rebounds, the total return will be higher. The botox specialist reported $4.08 billion in revenue, down 5.7% from last year. Non-GAAP income fell 15.4% to $1.45 billion. Encouragingly, sales of Botox rose 9.4%, while the Juvederm collection, Lo Loestrin and Vraylar all rose in the double digits. Although these products are a smaller part of total revenue, it is enough for management to forecast revenue of $15 billion - $15.3 billion this year. * 7 Stocks That Won Super Bowl Sunday With management forecasting lighter results for the year, why should investors buy AGN stock for the dividends? The firm has six late-stage clinical programs, plans of one to two new product launches annually and the company has strong margins. It made $5.64 billion in operating cash flow last year. This is more than the $976 million it needs for the dividend. Source: Shutterstock ### Sanofi (SNY) After settling at around $42 at the start of 2019, Sanofi (NASDAQ:SNY) rallied steadily to close at around $43.45 recently. Now, at its 50-day simple moving average, shares have a dividend yield of 4.28%. Sanofi's underperformance is unusual. Other than trading at a slightly higher valuation at a P/E of 22X, the company did not report any negative news. If anything, the collaborations that this biotech firm has with Regeneron Pharmaceuticals (NASDAQ:REGN) should bolster investor confidence. Regeneron's Dupixent is becoming a blockbuster hit for treating Atopic Dermatitis. Alongside its efforts with REGN, SNY is also supplying the active ingredient of avanafil to Vivus (NASDAQ:VVUS). Another promising aspect bolstering the case for SNY stock is that on Jan. 23, the Food and Drug Administration approved the use of Sanofi's Fluzone in young children. When it reports earnings on Feb. 7, the company should not bring up any negative surprises. It should be consistent like Q3's report where the company reported sales growing 6.3% (at constant exchange rates). Its Bioverativ acquisition should continue to contribute meaningfully to sales. Looking ahead, an EMA decision in the first half of this year for its oncology drug Libtayo, plus an FDA action date of Feb. 6 for Cablivi, which treats a rare blood disorder, should keep investor confidence high. As of this writing, Chris Lau held shares of ABBV. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 F-Rated Stocks That Could Break Your Portfolio * 5 Fintech Stocks to Buy As This Mega Trend Gains Steam * 10 Cold Weather Stocks to Heat Up Your Returns Compare Brokers The post 3 Biotech Stocks That Pay Solid Dividends appeared first on InvestorPlace.
U.S. large-cap stocks pushed higher again on Monday, with the S&P 500 posting a modest gain thanks to a surge in widely held momentum favorites in the technology sector. But the strength is uneven, with a number of sectors lagging badly. Healthcare in particular is falling behind, with a loss of 0.9%. The catalyst for the ongoing rise is the good feelings related to the dovish tilt by the Federal Reserve in recent weeks, with chairman Jerome Powell changing his tune on both the likely path of rate hikes this year and the ongoing drawdown of balance sheet assets. * 7 Stocks That Won Super Bowl Sunday The rally has pushed the S&P 500 up nearly 16% from the low set in late December, with the index now closing in on its 200-day moving average -- a level that proved to be difficult resistance throughout the end of 2018. If a breakthrough is going to happen, it depends on whether the market follows the strength or the weakness of the following six stocks: InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Hot Stocks: Apple (AAPL) Apple (NASDAQ:AAPL) shares are extending their recent breakout above their 50-day moving average, capping a 20% one off of its early January low thanks to good earnings results and budding excitement over the iPhone refresh coming later this year (with rumors of a three-camera setup). There is also a sense the company has regained some momentum with the well received iPad Pro as well. The company will next report results on April 30 after the close. Analysts are looking for earnings of $2.38 per share on revenues of $57.6 billion. When the company last reported on Jan. 29, earnings of $4.18 per share beat estimates by a penny on a 4.5% decline in revenues. ### Hot Stocks: Boeing (BA) Boeing (NYSE:BA) shares are pushing above their October high to break free into clean air, ending a sideways consolidation that started in late 2017, as the demand for new airlines seems insatiable amid bloated order books and increased travel activity. The company's recently reported earnings were a blowout, and more is expected as production ramps up. Analysts at Canaccord Genuity raised their price target to $380 on what they see as little risk to management's forward guidance. The company will next report results on April 24 before the bell. Analysts are looking for earnings of $4.25 per share on revenues of $25.2 billion. * 10 F-Rated Stocks That Could Break Your Portfolio When the company last reported on Jan. 30, earnings of $5.48 beat estimates by 93 cents on a 14.4% rise in revenues. ### Hot Stocks: Microsoft (MSFT) Microsoft (NASDAQ:MSFT) shares are revving up, cutting back above both their 50-day and 200-day moving average as the company adopts a position as the quiet, more professional member of the mega-cap tech stock cohort with its steady focus on corporate cloud business and its no-drama, spotlight-averse CEO Satya Nadella. The company will next report results on April 25 after the close. Analysts are looking for earnings of $1 per share on revenuers of $29.9 billion. When the company last reported on Jan. 30, earnings of $1.10 beat estimates by a penny on a 12.3% rise in revenues. ### Cold Stocks: Allergan (AGN) Allergan (NYSE:AGN) shares are cratering, down another 4.2% on Monday to cap a loss of more than 14% from the highs set just two weeks ago. Investors are getting cold feet after the company reported a drop in revenue as competitor Evolus (EOLS) received FDA approval for a Botox alternative to be used to reduce wrinkles and fine lines in patients. The company will next report results on April 29 before the bell. Analysts are looking for earnings of $3.57 per share on revenues of $3.5 billion. * 7 S&P 500 Stocks to Buy That Tore Up Earnings When the company last reported on Jan. 29, earnings of $4.29 beat estimates by 14 cents on a 5.7% decline in revenues. ### Cold Stocks: AbbVie (ABBV) AbbVie (NYSE:ABBV) shares are threatening to fall below their early November low, capping a decline of 17% from the highs reached in early December. A breakdown would set up a fall back to levels not seen since the summer of 2017 and deepen an already painful decline of 35% from its 2018 high. Investors have lost interest amid middling results and bio similar competition for Humira. The company will next report results on April 26 before the bell. Analysts are looking for earnings of $2.05 per share on revenues of $7.8 billion. When the company last reported on Jan. 25, earnings of $1.90 per share missed estimates by three cents on a 7.3% rise in revenues. ### Cold Stocks: DowDuPont (DWDP) Shares of DowDuPont (NYSE:DWDP) are falling to test critical support from a five-month consolidation range after bonking once again on resistance near the $60-a-share threshold. Results have been pressured by weakening demand from China as well as fears over rising recession risks here at home. The company will next report results on May 2 before the bell. Analysts are looking for earnings of 90 cents per share on revenues of $20.2 billion. * 7 Stocks With Too Much Riding On China When the company last reported on Jan. 31, earnings of 88 cents per share beat estimates by a penny on a 0.2% rise in revenues. As of this writing, William Roth did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 F-Rated Stocks That Could Break Your Portfolio * 5 Fintech Stocks to Buy As This Mega Trend Gains Steam * 10 Cold Weather Stocks to Heat Up Your Returns Compare Brokers The post 3 Red-Hot Stocks (And 3 That Aren't) appeared first on InvestorPlace.